Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 8/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.31 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.31 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.31 |
| ▸ | IGFBP5 | P24593 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30540594 | 0.95 | CD38 (0.36) | CD38ALOX15IGFBP3IGFBP5ALDH1A1 | |
| SCHEMBL30577602 | 0.85 | CD38 (0.36) | CD38 | |
| SCHEMBL30577575 | 0.84 | CD38 (0.35) | CD38ALDH1A1KDM4EHPGD | |
| SCHEMBL30540508 | 0.78 | KHK (0.34) | CD38 | |
| SCHEMBL30540565 | 0.78 | GPR35 (0.34) | — | |
| SCHEMBL30540650 | 0.78 | ANO1 (0.32) | — | |
| SCHEMBL30540673 | 0.76 | METTL3 (0.33) | ALOX15METTL3METTL14IGFBP3IGFBP5 | |
| SCHEMBL30540543 | 0.76 | MPO (0.41) | CD38METTL3METTL14KDM4E | |
| SCHEMBL25349795 | 0.75 | CD38 (0.34) | CD38ALOX15IGFBP3IGFBP5ALDH1A1 | |
| SCHEMBL30540502 | 0.75 | MPO (0.38) | CD38ALOX15IGFBP3IGFBP5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163047-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE, LTD. (KY) | 2025-05-22 | — | — | US | disclosed |
| EP-4476219-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BeiGene, Ltd. (KY) | 2024-12-18 | — | — | EP | disclosed |
| CN-118696043-A | Heterocyclic compounds, compositions thereof and methods of treatment therewith | 百济神州有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2023151636-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023151641-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163047-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | NFATC1, GZMB, IFNG | CD38 304/4885ALOX15 242/4885METTL3 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.